AstraZeneca’s experimental daily pill, elecoglipron, helped participants lose up to 11.8% of their body weight in a Phase 2 trial. As a potential alternative to injectable GLP-1 treatments, the drug shows promise for managing obesity. However, researchers emphasize that larger Phase 3 trials are necessary to confirm long-term safety and effectiveness before it can reach the market.